A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants
Latest Information Update: 27 Oct 2023
At a glance
- Drugs Pelacarsen (Primary)
- Indications Hyperlipoproteinaemia
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 15 Nov 2022 Status changed from recruiting to completed.
- 11 Oct 2022 Planned End Date changed from 13 Sep 2022 to 21 Oct 2022.
- 11 Oct 2022 Planned primary completion date changed from 13 Sep 2022 to 21 Oct 2022.